Anthracyclines remain among the most widely prescribed and effective anticancer agents. Unfortunately, life-threatening cardiotoxicity continues to compromise their usefulness. Despite more than four decades of investigation, the pathogenic mechanisms responsible for anthracycline cardiotoxicity have not been completely elucidated. In addition, new drugs and combination therapies often exacerba...

Taxanes are the most active drugs in the treatment of metastatic breast and ovarian cancer. Weekly therapy with paclitaxel produces notable activity, with remarkably low toxicity. Moreover, combination therapy with paclitaxel and fluorouracil (5-FU) exhibits high activity in anthracycline-pretreated breast cancer patients: recent studies report response rates of 54% to 69%. UFT plus oral leucov...

The anthracycline antibiotics have now been in use in curative chemotherapy protocols for over two decades. They are highly active against a wide range of haemopoietic and solid tumours in children and adults. Unfortunately, their antineoplastic use is limited by significant and irreversible cardiotoxicity, the full extent of which continues to emerge. As more children become long term survivor...

Anthracycline antibiotics are potent anticancer drugs widely used in the treatment of solidtumors and hematological malignancies. Because of their extensive clinical use and their toxiceffect on normal cells, in the present study the effect of these drugs on multipotent hematopoieticbone marrow cells was investigated employing, viability tests, PARP cleavage, Hoechst 33258staining, DNA fragment...

Introduction: Anthracyclines are one of the classes of chemotherapy drugs that  are widely used to treat many types of cancers including breast cancer. Taking this class of medications has a significant relationship with cardiac dysfunction. N-acetylcysteine has antioxidant properties and may be effective in preventing cardiac dysfunctions. In this study, we investigated the effect of N-acetylc...

alay et al. (1), in a population of apparently unselected patients eceiving their first 6 cycles of anthracyclines, found in their ontrol group a high incidence of functional cardiomyopathy: 24% f their patients had at the final examination an ejection fraction of 0% or less. This incidence of cardiac dysfunction is higher than he expected one for patients beginning their exposure to anthraycli...

BACKGROUND Moderate differences in efficacy between adjuvant chemotherapy regimens for breast cancer are plausible, and could affect treatment choices. We sought any such differences. METHODS We undertook individual-patient-data meta-analyses of the randomised trials comparing: any taxane-plus-anthracycline-based regimen versus the same, or more, non-taxane chemotherapy (n=44,000); one anthra...

Treatment of Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL) remains an unmet need in every day clinical practice. Pixantrone is approved by European Medicines Agency (EMA) for R/R DLBCL last generation anthracenedione developed to reduce the risk cardiotoxicity. However real-world data regarding efficacy and safety this agent are limited controversial. In our study we analyzed ...

chemotherapy is not recommended for the adjuvant treatment of breast cancer in any patient population. Anthracycline–taxane-based polychemotherapy regimens are, overall, considered superior to earliergeneration regimens and have the most significant impact on patient survival outcomes. Regimens with varying anthracycline and taxane doses and schedules are options; in general, paclitaxel given e...

Objective. To evaluate the alterations of Global longitudinsl strain (GLS) and it’s value for prediction cardiotoxicity low to moderate cumulative doses anthracyclines. Methods. Forty-nine women 50 ± 10 years old with breast cancer, treated anthracyclines (cumulative dose 251 60 mg/m2) were enrolled in study. Echocardiography GLS measurement was performed at baseline, end anthracycline treatmen...